SCHEMBL640576

SCHEMBL640576

COc1ccc(S(=O)(=O)n2c(=O)n(C(C(=O)N3CCOCC3)c3ccccc3)c3cc(Cl)ccc32)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 2/20 0.42
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
F10 P00742 4/20 0.39
USP2 O75604 2/20 0.39
MAPT P10636 2/20 0.39
HTT P42858 2/20 0.39
NPC1 O15118 1/20 0.39
MITF O75030 1/20 0.39
CHRM5 P08912 1/20 0.38
KDM4E B2RXH2 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL639656 0.93 PPARG (0.43) KMT2AMEN1PPARGPPARAALDH1A1
SCHEMBL641120 0.93 PPARG (0.43) KMT2AMEN1PPARGPPARAALDH1A1
SCHEMBL641108 0.92 MEN1 (0.43) KMT2AMEN1PPARGPPARAALDH1A1
SCHEMBL641164 0.91 ALDH1A1 (0.46) LMNAL3MBTL1KMT2AMEN1PPARG
SCHEMBL642204 0.91 PPARG (0.42) KMT2AMEN1PPARGPPARAALDH1A1
SCHEMBL642043 0.88 CHRM1 (0.40) KMT2AMEN1PPARGPPARAALDH1A1
SCHEMBL641231 0.88 MAPK1 (0.42) LMNAL3MBTL1KMT2AMEN1PPARG
SCHEMBL639751 0.87 MEN1 (0.43) KMT2AMEN1PPARGPPARASMN1; SMN2
SCHEMBL639914 0.86 PPARG (0.47) KMT2AMEN1PPARGPPARAALDH1A1
SCHEMBL641617 0.86 ALDH1A1 (0.43) KMT2AMEN1PPARGPPARAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791148-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use AbbVie Deutschland GmbH & Co. KG (DE) 2014-07-29 US disclosed
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2012-07-05 US disclosed
US-8119676-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use Abbott GmbH & Co. HG (DE) 2012-02-21 US disclosed
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2010-06-17 US disclosed
EP-2061769-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE Abbott GmbH & Co. KG (DE) 2009-05-27 EP disclosed
WO-2008025736-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A LMNA 886/4885L3MBTL1 3180/4885KMT2A 4356/4885
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A LMNA 886/4885L3MBTL1 3180/4885KMT2A 4356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.